Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 42,600 shares, a decline of 29.2% from the March 15th total of 60,200 shares. Approximately 1.2% of the shares of the stock are short sold. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is presently 1.4 days.

Insiders Place Their Bets

In other news, major shareholder Alexander Schornstein bought 24,999 shares of the firm's stock in a transaction on Wednesday, January 17th. The shares were bought at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the completion of the transaction, the insider now owns 655,357 shares in the company, valued at $6,134,141.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 2,066 shares of company stock worth $26,924. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Assembly Biosciences by 4.4% in the fourth quarter. Vanguard Group Inc. now owns 2,339,088 shares of the biopharmaceutical company's stock worth $1,918,000 after acquiring an additional 99,092 shares during the last quarter. Northern Trust Corp increased its stake in Assembly Biosciences by 21.3% in the fourth quarter. Northern Trust Corp now owns 131,182 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 23,066 shares during the last quarter. Marquette Asset Management LLC acquired a new position in Assembly Biosciences in the fourth quarter valued at $45,000. Acuitas Investments LLC acquired a new position in Assembly Biosciences in the fourth quarter valued at $218,000. Finally, Geode Capital Management LLC increased its stake in Assembly Biosciences by 12.2% in the second quarter. Geode Capital Management LLC now owns 507,649 shares of the biopharmaceutical company's stock valued at $584,000 after purchasing an additional 55,021 shares during the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on ASMB shares. StockNews.com upgraded Assembly Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, April 5th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Assembly Biosciences Trading Down 2.7 %

Shares of NASDAQ ASMB traded down $0.41 during trading on Friday, reaching $14.65. The company had a trading volume of 19,500 shares, compared to its average volume of 28,760. Assembly Biosciences has a twelve month low of $7.69 and a twelve month high of $20.04. The stock has a market capitalization of $80.28 million, a PE ratio of -0.88 and a beta of 0.57. The stock has a 50-day moving average price of $12.70 and a two-hundred day moving average price of $10.77.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.